English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [2318]
News [5343]
Articles [130]
Editorials [4]
Conferences [158]
elearning [13]
Lenalidomide with CD19 antibodies in L-MIND
Dr Kami Maddocks - Ohio State University, Columbus, USA
Lenalidomide with CD19 antibodies in L-MIND ( Dr Kami Maddocks - Ohio State University, Columbus, USA )
25 Jun 2017
Denosumab or zoledronic acid for bone disease in multiple myeloma
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Denosumab or zoledronic acid for bone disease in multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
25 Jun 2017
Extended followup indicates daratumumab with bortezomib and dexamethasone for...
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Extended followup indicates daratumumab with bortezomib and dexamethasone for relapsed MM ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
24 Jun 2017
Triplet therapy for all comers in the CLL-BAG trial
Dr Paula Cramer – University of Cologne, Cologne, Germany
Triplet therapy for all comers in the CLL-BAG trial ( Dr Paula Cramer – University of Cologne, Cologne, Germany )
24 Jun 2017
Disruption of BAFF-BCR crosstalk in CLL
Dr Alexey Danilov - Knight Cancer Institute, Portland, USA
Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )
24 Jun 2017
Interim analysis of the JULIET study
Prof Gilles Salles - Université Claude Bernard, Lyon, France
Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )
24 Jun 2017
400mg imatinib as good as 800mg for 10 year CML survival
Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany
400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )
23 Jun 2017
Carfilzomib combinations in ENDEAVOR and FORTE
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
23 Jun 2017
Deep molecular response to gilteritinib in CHRYSALIS trial
Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern...
Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )
23 Jun 2017
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed...
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Clinical potential of trastuzumab biosimilar CTP6
Prof Francisco Esteva - NYU Langone Medical Center, New York, USA
Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )
8 Jun 2017
<1...116117118119120...194>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top